Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

Ozer BH, Lindhorst SM, Merrell RT, Trevino CR, Rudnick JD, Avgeropoulos NG, Ramakrishna N, Khagi S, Rauf Y, Walbert T, Pan E, Youssef M, Fink KL, Mandel JJ, Taylor LP, Colman H, Dunbar EM, Paleologos N, Burton EC, Wu J, Leeper HE, Gonzalez J, Penas-Prado M, Raizer JJ, Veglia E, Craig S, Yuan Y, Chambers C, Wall K, Grajkowska E, Mendoza T, Armstrong TS, Gilbert MR

Open source

DOI: 10.64898/2026.06.22.26354817
Published: 2026 Jun 24
Container: medRxiv : the preprint server for health sciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.64898/2026.06.22.26354817,
  title = {Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.},
  author = {Ozer BH and Lindhorst SM and Merrell RT and Trevino CR and Rudnick JD and Avgeropoulos NG and Ramakrishna N and Khagi S and Rauf Y and Walbert T and Pan E and Youssef M and Fink KL and Mandel JJ and Taylor LP and Colman H and Dunbar EM and Paleologos N and Burton EC and Wu J and Leeper HE and Gonzalez J and Penas-Prado M and Raizer JJ and Veglia E and Craig S and Yuan Y and Chambers C and Wall K and Grajkowska E and Mendoza T and Armstrong TS and Gilbert MR},
  year = {2026},
  journal = {medRxiv : the preprint server for health sciences},
  doi = {10.64898/2026.06.22.26354817},
  url = {https://doi.org/10.64898/2026.06.22.26354817}
}

RIS

TY  - JOUR
TI  - Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
AU  - Ozer BH
AU  - Lindhorst SM
AU  - Merrell RT
AU  - Trevino CR
AU  - Rudnick JD
AU  - Avgeropoulos NG
AU  - Ramakrishna N
AU  - Khagi S
AU  - Rauf Y
AU  - Walbert T
AU  - Pan E
AU  - Youssef M
AU  - Fink KL
AU  - Mandel JJ
AU  - Taylor LP
AU  - Colman H
AU  - Dunbar EM
AU  - Paleologos N
AU  - Burton EC
AU  - Wu J
AU  - Leeper HE
AU  - Gonzalez J
AU  - Penas-Prado M
AU  - Raizer JJ
AU  - Veglia E
AU  - Craig S
AU  - Yuan Y
AU  - Chambers C
AU  - Wall K
AU  - Grajkowska E
AU  - Mendoza T
AU  - Armstrong TS
AU  - Gilbert MR
PY  - 2026
JO  - medRxiv : the preprint server for health sciences
DO  - 10.64898/2026.06.22.26354817
UR  - https://doi.org/10.64898/2026.06.22.26354817
ER  -

APA

BH, O., SM, L., RT, M., CR, T., JD, R., NG, A., N, R., S, K., Y, R., T, W., E, P., M, Y., KL, F., JJ, M., LP, T., H, C., EM, D., N, P., EC, B., J, W., HE, L., J, G., M, P., JJ, R., E, V., S, C., Y, Y., C, C., K, W., E, G., T, M., TS, A., & MR, G. (2026). Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.. medRxiv : the preprint server for health sciences. https://doi.org/10.64898/2026.06.22.26354817

Source records

pubmed · retrieved 2026-09-26T00:34:25.724Z